Clinical trial

Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients

NCT ID: 
NCT00682396
Study ID: 
RICMAC
Official title: 
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem Cell Transplantation in Patients With MDS or sAML: A Randomised Phase III Study
Conditions: 
  • Myelodysplastic Syndrome
  • Secondary Acute Myeloid Leukemia
The present study is a multicenter, prospective phase III-study comparing dose-reduced versus standard conditioning followed by allogeneic stem cell transplantation from related or unrelated donors in patients with MDS or secondary AML. The hypothesis is that dose-reduced conditioning will reduce the non-relapse mortality from 40% to 20% at one year after allogeneic stem cell transplantation.
Overall contact: 

Nicolaus Kroeger, Prof. Dr.
+49-40-42803-5864
nkroeger@uke [dot] uni-hamburg [dot] de

Clinical Trials Link: 

http://clinicaltrials.gov/show/NCT00682396